Abstract:Research demonstrates that the neural mechanisms underlying synaptic plasticity and learning and memory involve mobilization of AMPA-type neurotransmitter receptors at glutamatergic synaptic contacts, and that these mechanisms are targeted during neurodegenerative disease. Strengthening neural transmission occurs with insertion of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs) into synapses while weakening results from receptor withdrawal. A key player in the trafficking of AMPARs during plasticity and learning is the brain-derived neurotrophic factor (BDNF) signaling system. BDNF is a neurotrophic factor that supports neuronal growth and is required for learning and memory. Significantly, a primary feature of many neurodegenerative diseases is a reduction in BDNF protein as well as disrupted neuronal surface expression of synaptic AMPARs. The resulting weakening of synaptic contacts leads to synapse loss and neuronal degeneration that underlies the cognitive impairment and dementia observed in patients with progressive neurodegenerative disease such as Alzheimer's. In the face of these data, one therapeutic approach is to increase BDNF bioavailability in brain. While this has been met with significant challenges, the results of the research have been promising. In spite of this, there are currently no clinical trials to test many of these findings on patients. Here, research showing that BDNF drives AMPARs to synapses, AMPAR trafficking is essential for synaptic plasticity and learning, and that neurodegenerative disease results in a significant decline in BDNF will be reviewed. The aim is to draw attention to the need for increasing patient-directed clinical studies to test the possible benefits of increasing levels of neurotrophins, specifically BDNF, to treat brain disorders. Much is known about the cellular mechanisms that underlie learning and memory in brain. It can be concluded that signaling by neurotrophins like BDNF and AMPA-type glutamate receptor synaptic trafficking are fundamental to these processes. Data from animal models and patients reveal that these mechanisms are adversely targeted during neurodegenerative disease and results in memory loss and cognitive decline. A brief summary of our understanding of these mechanisms indicates that it is time to apply this knowledge base directly to development of therapeutic treatments that enhance neurotrophins for brain disorders in patient populations.

Ant imic rob ia l Therapy and Prevent ion in Febr i

BDNF as a Promising Therapeutic Agent in Parkinson’s Disease

BDNF/TrkB activators in Parkinson's disease: A new therapeutic strategy

Regulation of BDNF-TrkB Signaling and Potential Therapeutic Strategies for Parkinson's Disease

Role of BDNF in Central Motor Structures and Motor Diseases

Dysfunction in Brain-Derived Neurotrophic Factor Signaling Pathway and Susceptibility to Schizophrenia, Parkinson's and Alzheimer's Diseases

Effect of Cardiovascular and Metabolic Disease on Cognitive Test Performance and Cognitive Change in Older Adults

Dopaminergic reinforcement in the motor system: Implications for Parkinson's disease and deep brain stimulation

BDNF and synaptic plasticity, cognitive function, and dysfunction.

BDNF-TrkB Signaling in Mitochondria: Implications for Neurodegenerative Diseases

Dopaminergic modulation of striatal function and Parkinson’s disease

Regulation of AMPAR trafficking in synaptic plasticity by BDNF and the impact of neurodegenerative disease

Dopamine–endocannabinoid Interactions Mediate Spike-Timing-dependent Potentiation in the Striatum

BDNF signaling in context: From synaptic regulation to psychiatric disorders

[Research progress on striatal D2-MSNs plasticity mediated improvement of motor dysfunction by exercises in Parkinson's disease]

Brain-derived neurotrophic factor/tropomyosin receptor kinase B signaling in spinal muscular atrophy and amyotrophic lateral sclerosis

Emerging regenerative medicine and tissue engineering strategies for Parkinson’s disease

Striatal cell-type-specific molecular signatures reveal therapeutic targets in a model of dystonia

Potential Therapeutic Approach using Aromatic l-amino Acid Decarboxylase and Glial-derived Neurotrophic Factor Therapy Targeting Putamen in Parkinson's Disease

Dinitrogen formation by oxidative intramolecular N---N coupling in cis,cis-[(bpy)2(NH3)RuORu(NH3)(bpy)2]4+.

BDNF and Its Multirole Function in Neurogenesis, Synaptic Transmission and Neurodegenerative Diseases